CRBP Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 107673 min ago

@ $23.69

Išleistas: 14 vas. 2024 @ 16:41

Grąža: 44.58%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: 11.15 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases...

Stats
Šios dienos apimtis	90 155.00
Vidutinė apimtis	452 214
Rinkos kapitalizacija	359.39M
EPS	$0 ( 2024-03-12 )
Kita pelno data	( $-1.090 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.32
ATR14	$0.107 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Moran Sean F.	Buy	1 787	Common Stock
2024-04-10	Moran Sean F.	Sell	1 787	Employee Stock Option (right to buy)
2024-03-08	Cormorant Asset Management, Lp	Buy	8 862	Common Stock
2024-03-08	Cormorant Asset Management, Lp	Buy	156 597	Common Stock
2024-03-08	Cormorant Asset Management, Lp	Buy	61 668	Common Stock

INSIDER POWER
99.57
Last 95 transactions
Buy: 14 080 389 \| Sell: 365 661

Tūris Koreliacija

Ilgas: -0.13 (neutral)

Trumpas: -0.68 (moderate negative)

Signal:(47.691) Neutral

Corbus Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
VKTX	0.923
BLPH	0.919
CHMA	0.904
BTF	0.903
ALBO	0.902
SUMO	0.901
CMPI	0.901
NVCN	0.899
IMRX	0.885
NLTX	0.885

10 Labiausiai neigiamai susiję koreliacijos
MSBI	-0.949
BWFG	-0.948
NFBK	-0.946
CNOB	-0.944
ONB	-0.944
PFBC	-0.944
FBIZ	-0.943
PGC	-0.943
BCBP	-0.941
WSFS	-0.941

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Corbus Pharmaceuticals Koreliacija - Valiuta/Žaliavos

-0.34
( neutral )

-0.28
( neutral )

0.59
( weak )

0.25
( neutral )

0.31
( neutral )

0.46
( neutral )

Corbus Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-641 000 (0.00 %)
EPS:	$-10.31

FY	2023
Pajamos:	$0
Bruto pelnas:	$-641 000 (0.00 %)
EPS:	$-10.31

FY	2022
Pajamos:	$0
Bruto pelnas:	$-1.49M (0.00 %)
EPS:	$-13.39

FY	2021
Pajamos:	$881 705
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.